Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme

Trial Profile

Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Buparlisib (Primary) ; Carboplatin; Lomustine
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 08 Jul 2016 Planned End Date changed from 1 Apr 2016 to 1 Aug 2016.
    • 08 Jul 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Aug 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top